EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 320 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Genetic Signature May Help Tailor Treatment for Meningioma December 21, 2023 Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer March 15, 2022 Opinion: “We’ve been pushing for change for 20 years. We’re not... January 24, 2022 Army Veteran Gets Life-Saving Heart Transplant: ‘It’s A True Miracle’ November 29, 2021 Load more HOT NEWS Changes to chromosomes impact how children’s brain tumours respond to treatment Early cancer diagnosis and COVID-19: unpicking the impact of the pandemic Data Shows Women Are Not Getting Access To An Important Part... New Super-Microsurgical Procedure May Prevent Lymphedema in Breast Cancer Patients
